1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1.2.2 RNA Interference 1.2.3 SiRNA 1.2.4 MiRNA 1.2.5 Antisense RNA 1.3 Market by Application 1.3.1 Global Antisense & RNAi Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029 1.3.2 Oncology 1.3.3 Cardiovascular 1.3.4 Renal 1.3.5 Neurodegenerative 1.3.6 Respiratory 1.3.7 Genetic 1.3.8 Infectious Diseases 1.4 Study Objectives 1.5 Years Considered 1.6 Years Considered 2 Global Growth Trends 2.1 Global Antisense & RNAi Therapeutics Market Perspective (2018-2029) 2.2 Antisense & RNAi Therapeutics Growth Trends by Region 2.2.1 Global Antisense & RNAi Therapeutics Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Antisense & RNAi Therapeutics Historic Market Size by Region (2018-2023) 2.2.3 Antisense & RNAi Therapeutics Forecasted Market Size by Region (2024-2029) 2.3 Antisense & RNAi Therapeutics Market Dynamics 2.3.1 Antisense & RNAi Therapeutics Industry Trends 2.3.2 Antisense & RNAi Therapeutics Market Drivers 2.3.3 Antisense & RNAi Therapeutics Market Challenges 2.3.4 Antisense & RNAi Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Antisense & RNAi Therapeutics Players by Revenue 3.1.1 Global Top Antisense & RNAi Therapeutics Players by Revenue (2018-2023) 3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2018-2023) 3.2 Global Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Antisense & RNAi Therapeutics Revenue 3.4 Global Antisense & RNAi Therapeutics Market Concentration Ratio 3.4.1 Global Antisense & RNAi Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Antisense & RNAi Therapeutics Revenue in 2022 3.5 Antisense & RNAi Therapeutics Key Players Head office and Area Served 3.6 Key Players Antisense & RNAi Therapeutics Product Solution and Service 3.7 Date of Enter into Antisense & RNAi Therapeutics Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Antisense & RNAi Therapeutics Breakdown Data by Type 4.1 Global Antisense & RNAi Therapeutics Historic Market Size by Type (2018-2023) 4.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2024-2029) 5 Antisense & RNAi Therapeutics Breakdown Data by Application 5.1 Global Antisense & RNAi Therapeutics Historic Market Size by Application (2018-2023) 5.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Antisense & RNAi Therapeutics Market Size (2018-2029) 6.2 North America Antisense & RNAi Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 6.3 North America Antisense & RNAi Therapeutics Market Size by Country (2018-2023) 6.4 North America Antisense & RNAi Therapeutics Market Size by Country (2024-2029) 6.5 United States 6.6 Canada 7 Europe 7.1 Europe Antisense & RNAi Therapeutics Market Size (2018-2029) 7.2 Europe Antisense & RNAi Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 7.3 Europe Antisense & RNAi Therapeutics Market Size by Country (2018-2023) 7.4 Europe Antisense & RNAi Therapeutics Market Size by Country (2024-2029) 7.5 Germany 7.6 France 7.7 U.K. 7.8 Italy 7.9 Russia 7.10 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size (2018-2029) 8.2 Asia-Pacific Antisense & RNAi Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029 8.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2018-2023) 8.4 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2024-2029) 8.5 China 8.6 Japan 8.7 South Korea 8.8 Southeast Asia 8.9 India 8.10 Australia 9 Latin America 9.1 Latin America Antisense & RNAi Therapeutics Market Size (2018-2029) 9.2 Latin America Antisense & RNAi Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 9.3 Latin America Antisense & RNAi Therapeutics Market Size by Country (2018-2023) 9.4 Latin America Antisense & RNAi Therapeutics Market Size by Country (2024-2029) 9.5 Mexico 9.6 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size (2018-2029) 10.2 Middle East & Africa Antisense & RNAi Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 10.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2018-2023) 10.4 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2024-2029) 10.5 Turkey 10.6 Saudi Arabia 10.7 UAE 11 Key Players Profiles 11.1 Glaxo Smith Kline 11.1.1 Glaxo Smith Kline Company Detail 11.1.2 Glaxo Smith Kline Business Overview 11.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Introduction 11.1.4 Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.1.5 Glaxo Smith Kline Recent Development 11.2 Sanofi Aventis / Genzyme 11.2.1 Sanofi Aventis / Genzyme Company Detail 11.2.2 Sanofi Aventis / Genzyme Business Overview 11.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Introduction 11.2.4 Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.2.5 Sanofi Aventis / Genzyme Recent Development 11.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals 11.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Detail 11.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview 11.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Introduction 11.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development 11.4 Arbutus Biopharma Ltd. 11.4.1 Arbutus Biopharma Ltd. Company Detail 11.4.2 Arbutus Biopharma Ltd. Business Overview 11.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Introduction 11.4.4 Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.4.5 Arbutus Biopharma Ltd. Recent Development 11.5 Silence Therapeutics 11.5.1 Silence Therapeutics Company Detail 11.5.2 Silence Therapeutics Business Overview 11.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Introduction 11.5.4 Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.5.5 Silence Therapeutics Recent Development 11.6 Bio-Path Holdings Inc. 11.6.1 Bio-Path Holdings Inc. Company Detail 11.6.2 Bio-Path Holdings Inc. Business Overview 11.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Introduction 11.6.4 Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.6.5 Bio-Path Holdings Inc. Recent Development 11.7 Calando Pharmaceuticals 11.7.1 Calando Pharmaceuticals Company Detail 11.7.2 Calando Pharmaceuticals Business Overview 11.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Introduction 11.7.4 Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.7.5 Calando Pharmaceuticals Recent Development 11.8 ICo Therapeutics 11.8.1 ICo Therapeutics Company Detail 11.8.2 ICo Therapeutics Business Overview 11.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Introduction 11.8.4 ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.8.5 ICo Therapeutics Recent Development 11.9 Quark Pharmaceuticals 11.9.1 Quark Pharmaceuticals Company Detail 11.9.2 Quark Pharmaceuticals Business Overview 11.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Introduction 11.9.4 Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.9.5 Quark Pharmaceuticals Recent Development 11.10 Rexhan Pharmaceuticals 11.10.1 Rexhan Pharmaceuticals Company Detail 11.10.2 Rexhan Pharmaceuticals Business Overview 11.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Introduction 11.10.4 Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.10.5 Rexhan Pharmaceuticals Recent Development 11.11 Biomarin/Prosensa 11.11.1 Biomarin/Prosensa Company Detail 11.11.2 Biomarin/Prosensa Business Overview 11.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Introduction 11.11.4 Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.11.5 Biomarin/Prosensa Recent Development 11.12 Regulus Therapeutics 11.12.1 Regulus Therapeutics Company Detail 11.12.2 Regulus Therapeutics Business Overview 11.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Introduction 11.12.4 Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.12.5 Regulus Therapeutics Recent Development 11.13 Rxi Pharmaceuticals 11.13.1 Rxi Pharmaceuticals Company Detail 11.13.2 Rxi Pharmaceuticals Business Overview 11.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Introduction 11.13.4 Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.13.5 Rxi Pharmaceuticals Recent Development 11.14 Silenseed 11.14.1 Silenseed Company Detail 11.14.2 Silenseed Business Overview 11.14.3 Silenseed Antisense & RNAi Therapeutics Introduction 11.14.4 Silenseed Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.14.5 Silenseed Recent Development 11.15 Dicerna Pharmaceuticals 11.15.1 Dicerna Pharmaceuticals Company Detail 11.15.2 Dicerna Pharmaceuticals Business Overview 11.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Introduction 11.15.4 Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.15.5 Dicerna Pharmaceuticals Recent Development 11.16 Sirnaomics Inc. 11.16.1 Sirnaomics Inc. Company Detail 11.16.2 Sirnaomics Inc. Business Overview 11.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Introduction 11.16.4 Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2018-2023) 11.16.5 Sirnaomics Inc. Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029 Table 2. Key Players of RNA Interference Table 3. Key Players of SiRNA Table 4. Key Players of MiRNA Table 5. Key Players of Antisense RNA Table 6. Global Antisense & RNAi Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029 Table 7. Global Antisense & RNAi Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 8. Global Antisense & RNAi Therapeutics Market Size by Region (2018-2023) & (US$ Million) Table 9. Global Antisense & RNAi Therapeutics Market Share by Region (2018-2023) Table 10. Global Antisense & RNAi Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million) Table 11. Global Antisense & RNAi Therapeutics Market Share by Region (2024-2029) Table 12. Antisense & RNAi Therapeutics Market Trends Table 13. Antisense & RNAi Therapeutics Market Drivers Table 14. Antisense & RNAi Therapeutics Market Challenges Table 15. Antisense & RNAi Therapeutics Market Restraints Table 16. Global Antisense & RNAi Therapeutics Revenue by Players (2018-2023) & (US$ Million) Table 17. Global Antisense & RNAi Therapeutics Market Share by Players (2018-2023) Table 18. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense & RNAi Therapeutics as of 2022) Table 19. Ranking of Global Top Antisense & RNAi Therapeutics Companies by Revenue (US$ Million) in 2022 Table 20. Global 5 Largest Players Market Share by Antisense & RNAi Therapeutics Revenue (CR5 and HHI) & (2018-2023) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Antisense & RNAi Therapeutics Product Solution and Service Table 23. Date of Enter into Antisense & RNAi Therapeutics Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Antisense & RNAi Therapeutics Market Size by Type (2018-2023) & (US$ Million) Table 26. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2018-2023) Table 27. Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million) Table 28. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2024-2029) Table 29. Global Antisense & RNAi Therapeutics Market Size by Application (2018-2023) & (US$ Million) Table 30. Global Antisense & RNAi Therapeutics Revenue Market Share by Application (2018-2023) Table 31. Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million) Table 32. Global Antisense & RNAi Therapeutics Revenue Market Share by Application (2024-2029) Table 33. North America Antisense & RNAi Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 34. North America Antisense & RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million) Table 35. North America Antisense & RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million) Table 36. Europe Antisense & RNAi Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 37. Europe Antisense & RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million) Table 38. Europe Antisense & RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million) Table 39. Asia-Pacific Antisense & RNAi Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029 Table 40. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2018-2023) & (US$ Million) Table 41. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2024-2029) & (US$ Million) Table 42. Latin America Antisense & RNAi Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 43. Latin America Antisense & RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million) Table 44. Latin America Antisense & RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Antisense & RNAi Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 46. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2018-2023) & (US$ Million) Table 47. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2024-2029) & (US$ Million) Table 48. Glaxo Smith Kline Company Detail Table 49. Glaxo Smith Kline Business Overview Table 50. Glaxo Smith Kline Antisense & RNAi Therapeutics Product Table 51. Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 52. Glaxo Smith Kline Recent Development Table 53. Sanofi Aventis / Genzyme Company Detail Table 54. Sanofi Aventis / Genzyme Business Overview Table 55. Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product Table 56. Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 57. Sanofi Aventis / Genzyme Recent Development Table 58. Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Detail Table 59. Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview Table 60. Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product Table 61. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 62. Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development Table 63. Arbutus Biopharma Ltd. Company Detail Table 64. Arbutus Biopharma Ltd. Business Overview Table 65. Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product Table 66. Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 67. Arbutus Biopharma Ltd. Recent Development Table 68. Silence Therapeutics Company Detail Table 69. Silence Therapeutics Business Overview Table 70. Silence Therapeutics Antisense & RNAi Therapeutics Product Table 71. Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 72. Silence Therapeutics Recent Development Table 73. Bio-Path Holdings Inc. Company Detail Table 74. Bio-Path Holdings Inc. Business Overview Table 75. Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product Table 76. Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 77. Bio-Path Holdings Inc. Recent Development Table 78. Calando Pharmaceuticals Company Detail Table 79. Calando Pharmaceuticals Business Overview Table 80. Calando Pharmaceuticals Antisense & RNAi Therapeutics Product Table 81. Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 82. Calando Pharmaceuticals Recent Development Table 83. ICo Therapeutics Company Detail Table 84. ICo Therapeutics Business Overview Table 85. ICo Therapeutics Antisense & RNAi Therapeutics Product Table 86. ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 87. ICo Therapeutics Recent Development Table 88. Quark Pharmaceuticals Company Detail Table 89. Quark Pharmaceuticals Business Overview Table 90. Quark Pharmaceuticals Antisense & RNAi Therapeutics Product Table 91. Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 92. Quark Pharmaceuticals Recent Development Table 93. Rexhan Pharmaceuticals Company Detail Table 94. Rexhan Pharmaceuticals Business Overview Table 95. Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product Table 96. Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 97. Rexhan Pharmaceuticals Recent Development Table 98. Biomarin/Prosensa Company Detail Table 99. Biomarin/Prosensa Business Overview Table 100. Biomarin/Prosensa Antisense & RNAi Therapeutics Product Table 101. Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 102. Biomarin/Prosensa Recent Development Table 103. Regulus Therapeutics Company Detail Table 104. Regulus Therapeutics Business Overview Table 105. Regulus Therapeutics Antisense & RNAi Therapeutics Product Table 106. Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 107. Regulus Therapeutics Recent Development Table 108. Rxi Pharmaceuticals Company Detail Table 109. Rxi Pharmaceuticals Business Overview Table 110. Rxi Pharmaceuticals Antisense & RNAi Therapeutics Product Table 111. Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 112. Rxi Pharmaceuticals Recent Development Table 113. Silenseed Company Detail Table 114. Silenseed Business Overview Table 115. Silenseed Antisense & RNAi Therapeutics Product Table 116. Silenseed Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 117. Silenseed Recent Development Table 118. Dicerna Pharmaceuticals Company Detail Table 119. Dicerna Pharmaceuticals Business Overview Table 120. Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Product Table 121. Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 122. Dicerna Pharmaceuticals Recent Development Table 123. Sirnaomics Inc. Company Detail Table 124. Sirnaomics Inc. Business Overview Table 125. Sirnaomics Inc. Antisense & RNAi Therapeutics Product Table 126. Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2018-2023) & (US$ Million) Table 127. Sirnaomics Inc. Recent Development Table 128. Research Programs/Design for This Report Table 129. Key Data Information from Secondary Sources Table 130. Key Data Information from Primary Sources List of Figures Figure 1. Global Antisense & RNAi Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million) Figure 2. Global Antisense & RNAi Therapeutics Market Share by Type: 2022 VS 2029 Figure 3. RNA Interference Features Figure 4. SiRNA Features Figure 5. MiRNA Features Figure 6. Antisense RNA Features Figure 7. Global Antisense & RNAi Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million) Figure 8. Global Antisense & RNAi Therapeutics Market Share by Application: 2022 VS 2029 Figure 9. Oncology Case Studies Figure 10. Cardiovascular Case Studies Figure 11. Renal Case Studies Figure 12. Neurodegenerative Case Studies Figure 13. Respiratory Case Studies Figure 14. Genetic Case Studies Figure 15. Infectious Diseases Case Studies Figure 16. Antisense & RNAi Therapeutics Report Years Considered Figure 17. Global Antisense & RNAi Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029 Figure 18. Global Antisense & RNAi Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029 Figure 19. Global Antisense & RNAi Therapeutics Market Share by Region: 2022 VS 2029 Figure 20. Global Antisense & RNAi Therapeutics Market Share by Players in 2022 Figure 21. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense & RNAi Therapeutics as of 2022) Figure 22. The Top 10 and 5 Players Market Share by Antisense & RNAi Therapeutics Revenue in 2022 Figure 23. North America Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 24. North America Antisense & RNAi Therapeutics Market Share by Country (2018-2029) Figure 25. United States Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 26. Canada Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 27. Europe Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 28. Europe Antisense & RNAi Therapeutics Market Share by Country (2018-2029) Figure 29. Germany Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 30. France Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 31. U.K. Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 32. Italy Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 33. Russia Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 34. Nordic Countries Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 35. Asia-Pacific Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 36. Asia-Pacific Antisense & RNAi Therapeutics Market Share by Region (2018-2029) Figure 37. China Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 38. Japan Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 39. South Korea Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 40. Southeast Asia Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 41. India Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 42. Australia Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 43. Latin America Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 44. Latin America Antisense & RNAi Therapeutics Market Share by Country (2018-2029) Figure 45. Mexico Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 46. Brazil Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 47. Middle East & Africa Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 48. Middle East & Africa Antisense & RNAi Therapeutics Market Share by Country (2018-2029) Figure 49. Turkey Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 50. Saudi Arabia Antisense & RNAi Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million) Figure 51. Glaxo Smith Kline Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 52. Sanofi Aventis / Genzyme Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 53. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 54. Arbutus Biopharma Ltd. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 55. Silence Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 56. Bio-Path Holdings Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 57. Calando Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 58. ICo Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 59. Quark Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 60. Rexhan Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 61. Biomarin/Prosensa Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 62. Regulus Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 63. Rxi Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 64. Silenseed Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 65. Dicerna Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 66. Sirnaomics Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2018-2023) Figure 67. Bottom-up and Top-down Approaches for This Report Figure 68. Data Triangulation Figure 69. Key Executives Interviewed

Glaxo Smith Kline Sanofi Aventis / Genzyme Isis Pharmaceuticals/ Ionis Pharmaceuticals Arbutus Biopharma Ltd. Silence Therapeutics Bio-Path Holdings Inc. Calando Pharmaceuticals ICo Therapeutics Quark Pharmaceuticals Rexhan Pharmaceuticals Biomarin/Prosensa Regulus Therapeutics Rxi Pharmaceuticals Silenseed Dicerna Pharmaceuticals Sirnaomics Inc.